Twist Bioscience (TWST) filed a shelf registration statement with the US Securities and Exchange Commission on Thursday for the potential sale of securities from time to time in one or more offerings.
The filing covers common stock, preferred stock, debt securities, warrants and units, and includes a prospectus for the sale of up to $200 million of common stock under an at-the-market program.
The company said it intends to use any net proceeds for general corporate purposes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments